England and Wales reject Leo Pharma's eczema drug

The National Institute for Health and Care Excellence (NICE) has decided not to recommend Leo Pharma’s atopic dermatitis treatment tralokinumab.

Photo: Leo Pharma / PR

The public body responsible for providing guidance and advice for England and Wales, the National Institute for Health and Care Excellence (NICE), has announced in a press release that it does not recommend Leo Pharma’s Adtralza (tralokinumab) as a treatment for atopic dermatitis.

The Danish pharmaceutical firm’s drug was approved in Europe around a year ago, but NICE now questions whether Adtralza works better than other drugs against the disease also known as atopic eczema.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs